OncoMatch/Clinical Trials/NCT07480941
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Is NCT07480941 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Dual-target CAR-NK cells and Cyclophosphamide for glioblastoma.
Treatment: Dual-target CAR-NK cells · Cyclophosphamide · Fludarabine · Intracranial catheter/reservoir for locoregional delivery — This is a draft, ClinicalTrials.gov-style example record for a first-in-human Phase 1 study evaluating locoregional administration of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in adults with recurrent or progressive glioblastoma (GBM) or other high-grade glioma (HGG). Participants will undergo tumor antigen profiling for IL13Rα2, EGFR/EGFRvIII, and B7-H3 (CD276). Based on this assessment, each participant will receive the most suitable dual-target CAR construct to reduce antigen-escape risk.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: IL13RA2 expression above protocol-defined threshold (above protocol-defined threshold)
Tumor demonstrates expression of at least two of the following antigens above protocol-defined thresholds: IL13Rα2, EGFR (wild-type) and/or EGFRvIII, B7-H3 (CD276)
Required: EGFR wild-type expression above protocol-defined threshold (above protocol-defined threshold)
Tumor demonstrates expression of at least two of the following antigens above protocol-defined thresholds: IL13Rα2, EGFR (wild-type) and/or EGFRvIII, B7-H3 (CD276)
Required: EGFR EGFRvIII expression above protocol-defined threshold (above protocol-defined threshold)
Tumor demonstrates expression of at least two of the following antigens above protocol-defined thresholds: IL13Rα2, EGFR (wild-type) and/or EGFRvIII, B7-H3 (CD276)
Required: CD276 expression above protocol-defined threshold (above protocol-defined threshold)
Tumor demonstrates expression of at least two of the following antigens above protocol-defined thresholds: IL13Rα2, EGFR (wild-type) and/or EGFRvIII, B7-H3 (CD276)
Disease stage
Grade: 34 (WHO)
WHO grade 3 or 4
Prior therapy
Must have received: standard therapy
recurrent or progressive after standard therapy
Cannot have received: gene-modified cellular therapy (CAR-T cell therapy, CAR-NK cell therapy)
Prior gene-modified cellular therapy (e.g., prior CAR-T/CAR-NK) within 6 months
Cannot have received: therapy targeting IL13Rα2, EGFR/EGFRvIII, or B7-H3
Exception: where residual engineered cells could confound safety assessments
prior therapy targeting IL13Rα2, EGFR/EGFRvIII, or B7-H3 where residual engineered cells could confound safety assessments
Lab requirements
Blood counts
adequate hematologic function as defined by protocol laboratory criteria
Kidney function
adequate renal function as defined by protocol laboratory criteria
Liver function
adequate hepatic function as defined by protocol laboratory criteria
Adequate organ function (hematologic, renal, hepatic) as defined by protocol laboratory criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify